


Supplement


Supplementary Table 1: Statistically significant differences in the phagocytic index value and in the CD20 / HLA-A, -B, -C ratio between lymphoma cell lines¹

Cell lines	Phagocytic index		CD20 / HLA-A, -B, -C ratio	
	p-value	Summary	p-value	Summary
Granta 519 vs. DG-75	0.0015	**	0.1214	ns
Granta 519 vs. MEC2	0.0221	*	0.9102	ns
Granta 519 vs. Carnaval	0.0043	**	0.0001	****
Granta 519 vs. SU-DHL-4	<0.0001	****	0.0001	****
DG-75 vs. MEC2	0.1703	ns	0.1463	ns
DG-75 vs. Carnaval	<0.0001	****	0.0001	****
DG-75 vs. SU-DHL-4	<0.0001	****	0.0001	****
MEC2 vs. Carnaval	<0.0001	****	0.0001	****
MEC2 vs. SU-DHL-4	<0.0001	****	0.0001	****
Carnaval vs. SU-DHL-4	<0.0001	****	0.0001	****


¹Statistical analysis was performed with results depicted in Figure 1C using one-way ANOVA and Fisher's LSD test (ns, not significant).




Supplementary Figure 1: Purity, integrity and homogeneity of recombinant antibodies. (A) The purified antibodies CD47-IgG σ , LILRB1-IgG σ , LILRB2-IgG σ and RTX-DE were analyzed by microfluidic chip electrophoresis under reducing (lane 1) or non-reducing (lane 2) conditions. Four microliters of antibody preparations were loaded. Distinct protein bands were assigned to separated antibody heavy chains (HC), light chains (LC) or disulfide-bridged IgG molecules according to apparent molecular weights (MW). Upper and lower system peaks are indicated (S). (B) For Western transfer experiments, 1 μ g of purified antibodies was loaded on 12% (LILRB1-IgG σ) or 10% (CD47-IgG σ , LILRB2-IgG σ and RTX-DE) polyacrylamide gels, separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis under reducing conditions, and transferred to nitrocellulose membranes. Antibody heavy (HC) and light chains (LC) were detected using horseradish-peroxidase-conjugated Fc-specific goat anti-human-IgG (anti-hu Fc) and goat anti-human κ light chain (anti-hu κ) antibodies, respectively. (C) Antibodies CD47-IgG σ , LILRB1-IgG σ , LILRB2-IgG σ and RTX-DE were analyzed by gel filtration by injecting 100 - 400 μ g of proteins. Thyroglobulin (669 kDa), ferritin (440 kDa), conalbumin (75 kDa), ovalbumin (43 kDa, all purchased from Cytiva) and trastuzumab (145 kDa) were employed as molecular weight controls.




Supplementary Figure 2: Correlation analysis of HLA class I and CD20 expression levels and sensitivity to ADCP. The cell surface expression levels of CD20 and HLA-A, -B, -C molecules were determined for Granta 519, DG-75, MEC2, Carnaval and SU-DHL-4 cells by calibrated flow cytometry as illustrated in Figure 1. For each cell line, the specific antibody binding capacities (SABC) for HLA-A, -B, -C (**A**) and CD20 (**B**) were plotted against the calculated mean phagocytic index values for the treatment with RTX plus CD47-IgG σ . The solid line represents the best-fit curve, dotted lines indicate the 95% confidence interval.




Supplementary Figure 3: Antigen-specific binding of LILRB1-IgG σ and LILRB2-IgG σ antibodies. CHO-K1 cells were transiently transfected with either LILRB1 or LILRB2 cDNA expression vectors. Thus generated CHO-LILRB1 and CHO-LILRB2 cells, respectively, as well as mock transfected CHO-K1 cells (Mock) were incubated in buffer only or in the presence of antibodies LILRB1-IgG σ , LILRB2-IgG σ or HER2-IgG σ , as indicated. Each antibody was analyzed at a concentration of 50 μ g/ml. Secondary PE-conjugated F(ab')₂ fragments of goat anti-human Fc γ region antibodies were employed for detection. Purchased PE-conjugated anti-LILRB1 (LILRB1-PE) and anti-LILRB2 (LILRB2-PE) antibodies were used to verify efficient cell surface expression of LILRB1 and LILRB2 antigens, respectively. Antibody binding was analyzed by flow cytometry (black outlined peak: signal from buffer control, blue shaded peak: signals from antibodies, as indicated). Representative results from one out of three performed experiments are shown.



Supplementary Figure 4: LIRB2-IgG σ does not promote ADCP of lymphoma cells by macrophages. (A) LILRB1-IgG σ (LILRB1) or LILRB2-IgG σ (LILRB2) were combined with rituximab (RTX) and CD47-IgG σ (CD47) in 2 h ADCP assays with CFSE-labeled Carnaval cells and M0 macrophages (E:T cell ratio: 1:2). Phagocytic index values were determined by fluorescence microscopy. Antibodies were analyzed at a concentration of 10 μ g/ml. Data points represent results from individual experiments with macrophages from different donors. Horizontal lines indicate mean values \pm SD (w/o, without added antibody; *, $P \leq 0.05$; **, $P \leq 0.01$; ***, $P \leq 0.001$; ns, not significant; one-way ANOVA with Šidák's post-hoc test; $n = 11$). (B) ADCP of CFSE-labeled MEC2 ($n = 6$) or DG-75 ($n = 5$) lymphoma cells was analyzed with M0 macrophages without addition of an antibody (w/o) or with antibodies RTX, CD47-IgG σ , LILRB2-IgG σ , HER2-IgG σ (IgG σ) or trastuzumab (IgG1; each at a concentration of 10 μ g/ml) by fluorescence microscopy. (C) LILRB1-IgG σ and LILRB2-IgG σ were each combined with RTX and CD47-IgG σ in 2 h ADCP assays with DG-75 cells and M0 macrophages. Antibodies were analyzed at a concentration of 10 μ g/ml (*, $P \leq 0.05$; ns, not significant; one-way ANOVA with Šidák's post-hoc test; $n = 4$). (D) M1 and M2c macrophages were incubated with CFSE-labeled Carnaval cells and the antibodies RTX, CD47-IgG σ (CD47), LILRB2-IgG σ (LILRB2) and LILRB1-IgG σ (LILRB1) as assigned, each applied at a concentration of 10 μ g/ml. Mean phagocytic index values by antibody triple combinations were normalized to ADCP induced by RTX + CD47-IgG σ . Bars indicate mean values \pm SD (**, $P \leq 0.01$, ***, $P \leq 0.001$; one-way ANOVA with Šidák's post-hoc test). (E) DG-75 lymphoma cells were labeled with pHrodo[®] and analyzed as target cells for M0, M1 or M2c macrophages in the absence (w/o) or in the presence of RTX alone or in combination with IgG σ antibodies against CD47, LILRB1, LILRB2 or HER2 (IgG σ) as indicated (concentration: 10 μ g/ml). Data points represent mean values of red object count per image \pm SD ($n = 3$). The E:T cell ratio was 1:2.



Supplementary Figure 5: Single and multiple ADCP of Carnaval and DG-75 cells. CFSE-labeled Carnaval ($n = 9$) or DG-75 cells ($n = 6$) were incubated with M0 macrophages in the absence (w/o) or in the presence of antibodies rituximab (RTX), CD47-IgG σ (CD47), LILRB1-IgG σ (LILRB1) or HER2-IgG σ (IgG σ) as indicated (antibody concentration: 10 μ g/ml). After 2 h, the number of engulfed lymphoma cells by individual macrophages was determined. Heat maps indicate the percentage of macrophages grouped according to numbers of engulfed lymphoma cells.



Supplementary Figure 6: ADCP of patient CLL cells. CFSE-labeled CLL cells isolated from the peripheral blood of different patients were incubated with M0 macrophages (E:T cell ratio: 1:2) in the absence (w/o) or in the presence of antibodies trastuzumab (IgG1), rituximab (RTX), LILRB1-IgGσ (LILRB1), CD47-IgGσ (CD47) or HER2-IgGσ (IgGσ) as indicated. Each antibody was analyzed at a concentration of 10 μg/ml. After 2 h, ADCP was determined by fluorescence microscopy. Data points represent mean phagocytic index values ± SD from independent experiments using macrophages from two (CLL_10) or three different donors (all other samples).